Joe Nabhan
Chief Scientific Officer K2B Therapeutics
Seminars
Thursday 29th January 2026
Targeted Delivery of RNAi Therapeutics Using a Tumor Directed Protein Fragment
1:30 pm
- Featuring a proprietary tumor-directed protein, which mediates potent and selective biodistribution to tumors, as validated by higher payload concentration
- Demonstrating efficient functional delivery in vitro and in vivo of siRNA molecules to cancer cells for therapeutic application, achieving robust oncogene silencing and a profound anti-tumor effect
- Exploring the utility of siRNA delivery as an adjunct therapy to drug conjugates to sequentially disrupt oncogenic pathways and eradicate tumor cells, thereby overcoming mechanism-based resistance
